Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Home | Back to Search Results

Product Details for ANDA 208741

Expand all

DOXYCYCLINE HYCLATE (DOXYCYCLINE HYCLATE)
EQ 50MG BASE
Marketing Status: Discontinued

Active Ingredient: DOXYCYCLINE HYCLATE
Proprietary Name: DOXYCYCLINE HYCLATE
Dosage Form; Route of Administration: TABLET, DELAYED RELEASE; ORAL
Strength: EQ 50MG BASE
Reference Listed Drug: No
Reference Standard: No
TE Code: 
Application Number: A208741
Product Number: 001
Approval Date: Aug 11, 2023
Applicant Holder Full Name: LUPIN INC
Marketing Status:  Discontinued
Patent and Exclusivity Information

DOXYCYCLINE HYCLATE (DOXYCYCLINE HYCLATE)
EQ 60MG BASE
Marketing Status: Discontinued

Active Ingredient: DOXYCYCLINE HYCLATE
Proprietary Name: DOXYCYCLINE HYCLATE
Dosage Form; Route of Administration: TABLET, DELAYED RELEASE; ORAL
Strength: EQ 60MG BASE
Reference Listed Drug: No
Reference Standard: No
TE Code: 
Application Number: A208741
Product Number: 002
Approval Date: Aug 11, 2023
Applicant Holder Full Name: LUPIN INC
Marketing Status:  Discontinued
Patent and Exclusivity Information

DOXYCYCLINE HYCLATE (DOXYCYCLINE HYCLATE)
EQ 75MG BASE
Marketing Status: Discontinued

Active Ingredient: DOXYCYCLINE HYCLATE
Proprietary Name: DOXYCYCLINE HYCLATE
Dosage Form; Route of Administration: TABLET, DELAYED RELEASE; ORAL
Strength: EQ 75MG BASE
Reference Listed Drug: No
Reference Standard: No
TE Code: 
Application Number: A208741
Product Number: 003
Approval Date: Aug 11, 2023
Applicant Holder Full Name: LUPIN INC
Marketing Status:  Discontinued
Patent and Exclusivity Information

DOXYCYCLINE HYCLATE (DOXYCYCLINE HYCLATE)
EQ 80MG BASE
Marketing Status: Discontinued

Active Ingredient: DOXYCYCLINE HYCLATE
Proprietary Name: DOXYCYCLINE HYCLATE
Dosage Form; Route of Administration: TABLET, DELAYED RELEASE; ORAL
Strength: EQ 80MG BASE
Reference Listed Drug: No
Reference Standard: No
TE Code: 
Application Number: A208741
Product Number: 004
Approval Date: Aug 11, 2023
Applicant Holder Full Name: LUPIN INC
Marketing Status:  Discontinued
Patent and Exclusivity Information

DOXYCYCLINE HYCLATE (DOXYCYCLINE HYCLATE)
EQ 100MG BASE
Marketing Status: Discontinued

Active Ingredient: DOXYCYCLINE HYCLATE
Proprietary Name: DOXYCYCLINE HYCLATE
Dosage Form; Route of Administration: TABLET, DELAYED RELEASE; ORAL
Strength: EQ 100MG BASE
Reference Listed Drug: No
Reference Standard: No
TE Code: 
Application Number: A208741
Product Number: 005
Approval Date: Aug 11, 2023
Applicant Holder Full Name: LUPIN INC
Marketing Status:  Discontinued
Patent and Exclusivity Information

DOXYCYCLINE HYCLATE (DOXYCYCLINE HYCLATE)
EQ 120MG BASE
Marketing Status: Discontinued

Active Ingredient: DOXYCYCLINE HYCLATE
Proprietary Name: DOXYCYCLINE HYCLATE
Dosage Form; Route of Administration: TABLET, DELAYED RELEASE; ORAL
Strength: EQ 120MG BASE
Reference Listed Drug: No
Reference Standard: No
TE Code: 
Application Number: A208741
Product Number: 006
Approval Date: Aug 11, 2023
Applicant Holder Full Name: LUPIN INC
Marketing Status:  Discontinued
Patent and Exclusivity Information

DOXYCYCLINE HYCLATE (DOXYCYCLINE HYCLATE)
EQ 150MG BASE
Marketing Status: Discontinued

Active Ingredient: DOXYCYCLINE HYCLATE
Proprietary Name: DOXYCYCLINE HYCLATE
Dosage Form; Route of Administration: TABLET, DELAYED RELEASE; ORAL
Strength: EQ 150MG BASE
Reference Listed Drug: No
Reference Standard: No
TE Code: 
Application Number: A208741
Product Number: 007
Approval Date: Aug 11, 2023
Applicant Holder Full Name: LUPIN INC
Marketing Status:  Discontinued
Patent and Exclusivity Information

DOXYCYCLINE HYCLATE (DOXYCYCLINE HYCLATE)
EQ 200MG BASE
Marketing Status: Discontinued

Active Ingredient: DOXYCYCLINE HYCLATE
Proprietary Name: DOXYCYCLINE HYCLATE
Dosage Form; Route of Administration: TABLET, DELAYED RELEASE; ORAL
Strength: EQ 200MG BASE
Reference Listed Drug: No
Reference Standard: No
TE Code: 
Application Number: A208741
Product Number: 008
Approval Date: Aug 11, 2023
Applicant Holder Full Name: LUPIN INC
Marketing Status:  Discontinued
Patent and Exclusivity Information